Showing 81 - 100 results of 380 for search '"hypertension"', query time: 0.06s Refine Results
  1. 81
  2. 82

    High Blood Pressure: What You Need to Know by Linda B. Bobroff

    Published 2017-05-01
    Subjects: “…Hypertension (High Blood Pressure)…”
    Get full text
    Article
  3. 83
  4. 84

    High Blood Pressure: What You Need to Know by Linda B. Bobroff

    Published 2017-05-01
    Subjects: “…Hypertension (High Blood Pressure)…”
    Get full text
    Article
  5. 85
  6. 86
  7. 87

    Intravenous nicardipine and labetalol use in hypertensive patients with signs or symptoms suggestive of end-organ damage in the emergency department: a subgroup analysis of the CLUE trial by Brian Hiestand, Phillip Levy, W Frank Peacock, Brigitte M Baumann, Richard M Nowak, Amy Hsu, Joseph Varon, Chad M Cannon, David M Cline, Pierre Borczuk, Abhinav Chandra, Deborah B Diercks, Preeti Jois, Brian Kaminski, Jon W Schrock

    Published 2013-03-01
    “…On multivariable modelling with adjustment for gender and clinical site, nicardipine patients were more likely to be in TR by 30 min than patients receiving labetalol (OR 3.65, 95% CI 1.31 to 10.18, C statistic=0.72).Conclusions In the setting of hypertension with suspected EOD, patients treated with nicardipine are more likely to reach prespecified SBP targets within 30 min than patients receiving labetalol.Clinical Trial Registration NCT00765648, clinicaltrials.gov…”
    Get full text
    Article
  8. 88

    Cost-effectiveness of leveraging existing HIV primary health systems and community health workers for hypertension screening and treatment in Africa: An individual-based modeling study. by Matthew D Hickey, James Ayieko, Jane Kabami, Asiphas Owaraganise, Elijah Kakande, Sabina Ogachi, Colette I Aoko, Erick M Wafula, Norton Sang, Helen Sunday, Paul Revill, Loveleen Bansi-Matharu, Starley B Shade, Gabriel Chamie, Laura B Balzer, Maya L Petersen, Diane V Havlir, Moses R Kamya, Andrew N Phillips

    Published 2025-01-01
    “…<h4>Background</h4>Cardiovascular disease (CVD) morbidity and mortality is increasing in Africa, largely due to undiagnosed and untreated hypertension. Approaches that leverage existing primary health systems could improve hypertension treatment and reduce CVD, but cost-effectiveness is unknown. …”
    Get full text
    Article
  9. 89

    Efficacy of Chinese traditional quadruple single pill combination versus valsartan/hydrochlorothiazide for the treatment of hypertension (COSPQ-BP): study protocol for randomised controlled study by Kai Liu, Yu Yan, Xin Zhang, Yanan Li, Yuanyuan Yao, Lu Liu, Runyu Ye, Si Wang, Xiangyu Yang, Xiaoping Chen, Shanshan Jia, Qingtao Meng, Xianghao Zuo

    Published 2025-02-01
    “…Introduction Hypertension constitutes the primary health burden of cardiovascular diseases, and the global control of blood pressure (BP) remains insufficient. …”
    Get full text
    Article
  10. 90
  11. 91
  12. 92
  13. 93
  14. 94

    Using Real World Evidence to Describe Pulmonary Arterial Hypertension Treatment Patterns, Healthcare Resource Utilization, and Costs Associated with PDE-5 Inhibitor Monotherapy by George Ruiz, Jason Yeaw, Cassandra A. Lickert, Ajita P. De, Rolin L. Wade, Janis Pruett, William Drake

    Published 2018-01-01
    “…**Background:** Pulmonary arterial hypertension (PAH) is described by proliferation of small pulmonary arteries leading to increased pulmonary vascular resistance, right ventricular failure, and death. …”
    Get full text
    Article
  15. 95
  16. 96

    Comparison of Healthcare Encounters and Drug Persistence in Patients With Pulmonary Arterial Hypertension Receiving Oral Selexipag, Inhaled Iloprost, or Parenteral Treprostinil: A Retrospective Database Analysis by Ci Song, Peter Kunovszki, Amélie Beaudet

    Published 2022-06-01
    “…Eligible patients were ≥18 years of age with ≥1 ICD-9-CM or ICD-10-CM diagnosis code indicating pulmonary hypertension and no diagnosis code suggesting Group 3–5 pulmonary hypertension. …”
    Get full text
    Article
  17. 97
  18. 98
  19. 99
  20. 100